On March 13, 2019, the Board of Directors of Aptorum Group Limited appointed Dr. Lee as the Head of R&D of the Company, effective April 1, 2019. Dr. Thomas Lee served as Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited from January 2018 to February 2019. Dr. Lee has entered into an employment agreement, effective April 1, 2019 which amended his original agreement with the Company to reflect his new position as of Head of R&D. On March 13, 2019, the company appointed Dr. Ng as the COO of the Company, effective on April 1, 2019. Dr. Angel Ng served as the Chief Operating Officer of Aptorum Therapeutics Limited from September 2017 to February 2019. During this time, Dr. Ng led Aptorum Therapeutics Limited and its subsidiaries’ operations and business strategies. Dr. Ng has extensive experience in project management with Innovation and Technology government funds and academic institutions. On March 13, 2019, Dr. Keith Chan resigned from his position as Chief Scientific Officer. Dr. Chan’s decision to resign is not the result of any dispute or disagreements with the Company on any matter relating to the Company's operations, policies or practices, in fact, Dr. Chan accepted a position on newly created Scientific Advisory Board.